Biogen (Nasdaq: BIIB) has reported revenue of $3.5 billion for the first quarter of 2020, up 1%, with income at $1.4 billion or $8.08 per share, up from $7.15 per share.
The results were driven by better demand and a bigger-than-expected profit on spinal muscular atrophy (SMA) drug Spinraza (nusinersen), and multiple sclerosis (MS) drug Tecfidera (dimethyl fumarate).
While the performance exceeded many analysts’ expectations, investors may be concerned about a delay to a planned regulatory submission for the investigational Alzheimer’s drug aducanumab.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze